Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06323044 · ClinicalTrials.gov registry record · NA

MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence

A NA study of Acute Lymphoblastic Leukemia, sponsored by Roswell Park Cancer Institute.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT06323044 is a NA study of Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 150 participants, below the 381-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06323044, a NA study of Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

This clinical trial identifies and addresses barriers to pediatric medication adherence among families of children with acute lymphoblastic leukemia. Pediatric nonadherence (noncompliance) to medication is a significant public health problem, and rigorous research repeatedly documents that nonadherence increases risk for hospitalization, healthcare cost, disease progression, and death. Pediatric acute lymphoblastic leukemia (ALL) patients who miss 5% of 6-mercaptopurine (6-MP) doses within the 2-year 6-MP regimen have a 2.7-fold risk of cancer that comes back after a period of improvement (relapse). To address these families' needs, researchers have developed MedSupport, a theory-based multilevel intervention with targets at the organizational, healthcare team, and caregiver levels that is designed to address root barriers to medication adherence. This study is being done to better understand families' experiences giving their child oral chemotherapy at home and to help families cope with the day-to-day challenges of giving their child medication.

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Medical Device Usage and Evaluation
  • OTHER Best Practice
  • OTHER Electronic Health Record Review
  • OTHER Interview

Study Locations (1)

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2025-02-11
Est. Completion 2029-03-31
Phase NA

Sponsor

Roswell Park Cancer Institute

365 total trials

What the Registry Record Tells You About NCT06323044

The ClinicalTrials.gov registry entry for NCT06323044 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 381-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (61% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06323044 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06323044 about?

NCT06323044 is a clinical study titled "MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence". This clinical trial identifies and addresses barriers to pediatric medication adherence among families of children with acute lymphoblastic leukemia. Pediatric nonadherence (noncompliance) to medication is a significant public health problem, and rigorous research repeatedly documents that nonadhere...

What is the current status of trial NCT06323044?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2025-02-11. Estimated completion is 2029-03-31.

What conditions does trial NCT06323044 study?

This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia.

What interventions are being tested in trial NCT06323044?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Medical Device Usage and Evaluation (OTHER), Best Practice (OTHER), Electronic Health Record Review (OTHER), Interview (OTHER).

Who is sponsoring clinical trial NCT06323044?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06323044 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Lymphoblastic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.